Contributor Page
Smart & Biggar/Fetherstonhaugh
 
Email  |  Website  |  Articles
Contact Details
Tel: +1 416 5935514
Fax: +1 416 5911690
1100-150 York Street
Toronto
ON M5H 3S5
Canada
By Urszula Wojtyra
This is a new consolidated publication that will communicate updates to CADTH's drug review process.
By Andrew Mandlsohn
Patented Medicine Prices Review Board releases August 2018 NEWSletter.
By Andrew Mandlsohn
Participants can provide their feedback online until September 28, 2018 or in writing to the Council.
By Katie Lee
The Federal Court of Appeal found that the application judge made no reviewable error in finding that the TPD's decision was not improperly motivated, and dismissed the appeal.
By Abigail Smith
Health Canada announced it will move forward with Phase III of its prescription drug product transparency initiatives.
By Andrew Mandlsohn
The Report includes information regarding trends in listing on the Patent Register and the Register of Innovative Drugs, as well as related court activity.
By Brandon Heard
The Court concluded that both claims were obvious and that the 936 Patent failed to meet the criteria for a valid selection patent.
By Katie Lee
Justice Manson found the claims were obvious
By Urszula Wojtyra
Rather, the Court's role is to determine whether the plaintiff raises an arguable case such that it is not plain and obvious the action will fail.
By Mark Evans, Jamie-Lynn Kraft
Non-Canadian retailers can breathe a sigh of relief thanks to the Federal Court of Canada's decision in Dollar General Corporation v 2900319 Canada Inc, 2018 FC 778
By Lynn Ing
Consultation on the new MOPOP section is open until August 10, 2018.
By Katie Lee
According to the notice, these aligned reviews are expected to reduce duplication and time lags between Health Canada market authorization and HTA recommendations.
By Urszula Wojtyra
Tobacco companies cannot compel production of health records in British Columbia's lawsuits to recover health care costs related to tobacco exposure.
By Abigail Smith
These changes are summarized in CDR Update – Issue 138, and will be enforced for all submissions and resubmissions received on or after July 27, 2018.
By Andrew Mandlsohn
Patented Medicine Prices Review Board's multi-stakeholder Steering Committee holds first meeting